anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention provides positively-charged water-soluble diclofenac prodrugs with high skin penetration velocity. In a &#39;&#39;structural formula 1&#39;&#39; of a general formula (1), novel positively-charged water-soluble diclofenac prodrugs are designed and synthesized. The compounds as shown in the above-mentioned &#39;&#39;structural formula 1&#39;&#39; of the general formula (1) can be synthesized by reaction of functionalized derivatives (like acid halides or mixed anhydrides) of diclofenac with proper alcohol, thioalcohol or amine. Positively-charged amino groups on prodrug molecules greatly improve the solubility of a drug, and promote the drug to enter cytoplasm by combination with negative charges on biological membrane phosphate terminal groups. Experimental results show that the prodrug, i.e., 2-[(2,6-dichlorophenyl)amino]phenylacetate diethylaminoethyl acetate, has a human skin penetration velocity which is nearly 250 times as fast as the human skin penetration velocity of the prodrugs, i.e., 2-[(2,6-dichlorophenyl)amino]phenylacetate (diclofenac) and 2-[(2,6-dichlorophenyl)amino]phenylacetate ethyl. In plasma, more than 90% of the prodrugs can return to a parent drug in a few minutes. The prodrugs can be applied in medicine to treat human or animal states that any diclofenac can treat; in treatment, oral administration and transdermal administration are available, so that most of side effects of diclofenac are avoided, wherein the most significant side effects comprise gastrointestinal discomforts like indigestion, bleeding in stomach and duodenal, gastric ulcer and gastritis. Through a controlled release transdermal administration system of the prodrugs, the plasma drug concentration is stabilized in an optimal therapeutic level, so the treatment effects are improved, and the side effects of diclofenac are decreased.
PURPOSE: To prevent/treat pneumocystis carinii pneumonia(PCP) without any concomitant significant toxic reaction by administering pentamidine in the form of aerosol spray with specific particulate size. CONSTITUTION: A patient subject to or already affected by PCP is administered with an effective dose of pentamidine; p,p&#39;-(pentamethylenedioxy)dibenzamidine or a pharmaceutically permissible salt thereof (e.g. isethionate) in the form of aerosol spray with particulate size being 0.5-8.0μm in aerodynamic diameter. For the aerosol spray, particulates each 0.5-8μm in diameter preferably account for &gt;=55wt.% of the whole particulates, and the mass median aerodynamic diameter is pref. 1-6 (esp. 1-4)μ; and the aerosol spray is preferably produced by the use of an ultrasonic nebulizer. The dose of the pentamidine is 1-200 (pref. 45-75)mg for preventing PCP.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a Maillard reaction inhibitor and a cosmetic composition or a food enabling prevention and improvement of various kinds of diseases involving Maillard reaction, e.g. impartation of gloss/tenseness to the skin/scalp, prevention or improvement of skin aging represented by crease/flabbiness, etc., of the skin and suppression or improvement of complications derived from diabetes mellitus.  &lt;P&gt;SOLUTION: The Maillard reaction inhibitor comprises citric acid or its salt. The cosmetic composition or the food is composed by mixing the Maillard reaction inhibitor. The Maillard reaction inhibitor has excellent Maillard reaction inhibiting action. The cosmetic composition and the food each are obtained by using the Maillard reaction inhibitor.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
FIELD: medicine.SUBSTANCE: invention relates to radionuclide diagnostics and transplantation, and can be used for determining mitochondrial myocardial dysfunction after cardiac transplantation using a radionuclide method. Radiopharmaceutical is administered onceTc-technetryl. Early and delayed scintigraphic examination is performed 45-60 minutes and 4-6 hours after the radiopharmaceutical introduction to obtain scintigraphic images of 17 myocardial segments. Average count of pulses in each of 17 segments of early and delayed images is determined. Further, the radiopharmaceutical elutriation coefficient (RE) in each segment is determined by formula: RE = ((N*e-N)/(N*e)*(4/t))*100. N1 is average pulse count in a specific segment on an early scintigraphic image. N2 is average count of pulses in a specific segment on a delayed scintigraphic image. t is time interval in hours between delayed and early phases of scintigraphic examination. λ is the radiopharmaceutical decay constant. Conclusion on mitochondrial dysfunction is made for each segment when obtaining the value of RE &gt; 17.4±5.2.EFFECT: method provides higher prognostic value and accuracy of determining the prevalence of mitochondrial myocardial dysfunction and clinical effectiveness for patients after heart transplantation, as well as reducing the radiation exposure of the study by evaluating the early and delayed images with a single administration of radiopharmaceuticalTc-MIBI by calculating its washing-out coefficient in each segment of heart.1 cl, 15 dwg, 1 tbl, 3 ex
Methods and systems for managing a user&#39;s health habits. Various embodiments of the invention allow the user to register habits to a habit registry. Relevant sensor and other data is collected contemporaneously with the registration of the behavior and is stored in association with the registered habit. In normal use, a configured processor attempts to detect occurrences of a previously registered habit by comparing subsequently collected data to previously stored data. When collected and stored data match, a registered health habit is detected, the occurrence may be added to a health habit log, and the feedback may be provided to the user. The feedback assists the user to achieve his goals in health habit management.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an excellent anti-stress agent by combining GABA, γ(gamma)-aminobutyric acid, with Apocynum venetum extract.  &lt;P&gt;SOLUTION: The anti-stress agent includes GABA and Apocynum venetum extract. GABA is a food material known to have a relaxing effect. While, Apocynum venetum extract is reported to have antidepressant activity and antianxiety action. From the fact that it is suggested that Apocynum venetum extract acts an agonist of GABA receptor. A relaxing effect is expected to increase by simultaneous intake of GABA and Apocynum venetum extract. A composition obtained by combining GABA with Apocynum venetum extract is found to exhibit excellent anti-stress action and to be suitable as a therapeutic agent and preventive for stress, verifies at the first time that it has stress-reducing effect on human and the composition obtained by combining GABA with Apocynum venetum extract exhibits stronger effect than their single use.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To simply and efficiently produce the subject compound useful as a medicine having antiinflammatory, analgesic and antipyretic actions by reacting a benzyl halide derivative with a specific compound in the presence of a phase-transfer catalyst and then hydrolyzing the resultant compound. SOLUTION: A compound represented by formula I (R&lt;1&gt; is H or a lower alkyl; R&lt;2&gt; is a lower alkyl; X is a halogen) is reacted with a compound represented by formula II [R&lt;3&gt; is a lower alkyl; (n) is 1-2] in an amount of 1-1.5 equiv. based on the compound represented by formula I in the presence of a base in an amount of 1.1-10 equiv. based on the compound represented by formula I by using a phase-transfer catalyst such as tetraethylammonium chloride in an amount of 1-50 wt.%, preferably 2-10 wt.% based on the compound represented by formula I in a solvent at a reactional temperature which is not especially limited but usually ambient temperature to about the boiling point temperature of the solvent usually for 2-5 hr to provide a compound represented by formula III.  The resultant compound is then brought into contact with an acid in the presence of a solvent such as CH3 OH and hydrolyzed. The decarboxylating reaction of the resultant product is subsequently carried out at a reactional temperature between ambient temperature and the boiling point of the solvent for usually 2-20 hr to produce the objective compound represented by formula IV.
&lt;P&gt;PROBLEM TO BE SOLVED: To allow a person to be measured to receive various services by enlarging the usage range of biological information which is detected from the person to be measured.  &lt;P&gt;SOLUTION: The biological information of a user A is collected by a biological information collecting device 1 and transmitted from a user terminal 2 to a processing server 3. The processing server 3 performs analysis, based on a prescribed algorithm concerning the biological information and stores a diagnosis result. The processing server 3 stores the biological information and the transmission destination and transmission condition of the diagnosis result (a transmission period and a transmission content), and transmits information with a designated content to the transmission destination corresponding to the transmission condition. When the information is transmitted to service providing terminal device 20, for example, the device 20 performs transfer or a service indication to an insurance company 25d or a care company 25a, so that the user A receives the prescribed service. Besides, the processing server 3 transmits a notification to report an abnormality to the terminal B of a person B who is the family of the user A, so that the user A receives a rescue, etc.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
The novel compounds correspond to the formula I, in which the substituents have the meaning given in Patent Claim 1. These compounds are prepared by reaction of a compound of the formula II with a compound of the formula III, Y and Z in each case being different and either denoting hydrogen or the group -CH2-CH(OR1)-CH2-V and V being chlorine, bromine or iodine, or, if R1 is hydrogen, can also form the ethylene oxide ring together with this hydroxyl group. If appropriate, one or two nitro groups in a compound of the formula I obtained can be reduced to amino groups and/or the compounds obtained can be acylated with an acid or an acid derivative corresponding to the radical R1. The compounds obtained can be converted into their acid addition salts. The novel compounds are pharmacodynamically active and are suitable as an active component in medicaments. &lt;IMAGE&gt;
The invention discloses a graphene suppository and a preparation method and application thereof. The traditional Chinese medicine suppository is prepared from, by weight, 1-5 parts of graphene, 20-28 parts of honey-fried honeycombs, 15-23 parts of Japanese banana flowers, 18-26 parts of tarenna attenuata (Voigt) Hutch. and 1-8 parts of omphalia. The preparation method comprises the steps that honey-fried honeycombs and Japanese banana flowers are smashed and sieved, 20% of ethanol solution is added, sealing heat preservation treatment, ultrasonic treatment and centrifugal separation are conducted, and supernatant is obtained; tarenna attenuata (Voigt) Hutch. and omphalia are smashed and sieved, absolute ethyl alcohol is added, extraction is conducted twice, the two extracting solutions are mixed and concentrated, acetone is added, all the materials are stirred to be uniform, refrigerated and subjected to vacuum evaporation to recycle acetone, and residual liquid is obtained; graphene is smashed, sieved and stir-fried, and treated graphene is obtained; the supernatant and the residual liquid are mixed and stirred, treated graphene is added, ultrasonic treatment and heat preservation are conducted, and the suppository is obtained. The graphene suppository is definite and stable in therapeutic effect on Behcet&#39;s disease, quick in efficacy, high in cure rate and free of toxic and side effects, the Behcet&#39;s disease does not relapse after being cured, and the graphene suppository is safe to use and harmless to the heart, liver and kidney.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an antioxidant, a skin whitening agent, an anti-aging agent, a slimming agent, a cyclic AMP phosphodiesterase inhibitor, a skin cosmetic or a food and drink containing a natural extract.  &lt;P&gt;SOLUTION: An extract from Tetrastigma planicaule (Hook.) Gagnep. is contained in the antioxidant, the skin whitening agent, the anti-aging agent, the slimming agent or the cyclic AMP phosphodiesterase inhibitor as an active ingredient. The extract from Tetrastigma planicaule (Hook.) Gagnep. is compounded with the skin cosmetic or the food and drink.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PURPOSE:To obtain the subject pigment suitable for a colorant by adding an aqueous solution containing iron ions to an aqueous suspension of lamellar mica particles, further adding an aqueous solution of an alkali metal hydroxide or carbonate and coating the mica particles with black iron oxide. CONSTITUTION:An aqueous suspension of lamellar mica particles is stirred with heating in advance. On the other hand, urea and an oxidizing agent capable of oxidizing a ferrous salt are dissolved in an iron ion-containing aqueous solution having the (Fe&lt;3+&gt;/Fe&lt;2+&gt;) ratio adjusted to (0.01-0.4) and the resultant solution is then added to the above-mentioned suspension. An aqueous solution of an alkali metal hydroxide or a alkali metal carbonate, e.g. sodium hydroxide is further added thereto to coat the surface of the lamellar mica particles with black iron oxide. The resultant coated lamellar mica particles are then filtrated, water washed and subsequently heat treated at room temperature or &lt;=200 deg.C in an atmosphere of oxygen or air, thus obtaining the objective pigment.
The subject matter of the invention relates to a solid oral composition of isosorbide-5-mononitrate in the form of a controlled release tablet which can be divided into several parts. The tablet is marked by the presence of scoring in a direction perpendicular to its length and height of a depth more than 1/2 and approximately 2/3 of its height. The broken surface is thus reduced so that the maximum increase in the area of the tablet resulting from breakage into at least three pieces is always less than 15%. This ensures uniform release of the active ingredient of the fragmented pharmaceutical form in comparison with the intact tablet. The tablet is also marked by the high physical stability of the active ingredient. &lt;IMAGE&gt;
PROBLEM TO BE SOLVED: To obtain the subject composition high in polymerization speed, excel lent in light resistance, usable together with an acidic monomer and good in storage stability by using a polymerizable monomer, a specific photopolymeriza tion initiator and a specified N-phenylglycine derivative as a reducing agent. SOLUTION: This photopolymerization composition comprises a monomer having a polymerizable olefinic unsaturated group, a carbonyl compound absorbing light having wavelengths of 400-700nm as a photopolymerization initiator, and a compound of the formula (R&lt;1&gt; is an electron-attracting group, namely cyano, an alkylcarbonyl, an alkoxycarbonyl, etc.; R&lt;2&gt; is H, an alkyl) as a reducing agent. The introduction of the electron-attracting group to the aromatic ring of the N-phenyl glycine in the compound of the formula enables to shorten the polymerization time and improve the storage stability of the photopolymerization composition. The introduction of the substituent to the N atom enables to improve the solubility of the monomer and the light resistance of the cured product.  The compound of the formula is preferably N-(4-cyanophenyl)-N- methylglycine, and the photopolymerization initiator is preferably camphor quinone.
Stable solid β-lactam antibiotics for injections contain the antibiotic in acidic or amphoteric form together with a basic compd. in the presence of an atm. contg. &gt;=1% by vol. CO2. The base is present at 0.8-6.0 equiv/equiv antibiotic.  Thus, 14.818kg ceftazidime and 1.725kg Na2CO3 are mixed under sterile conditions and each 250mg of the mixt. is poured into injection vials and flushed with CO2 before sealing with a rubber and metal closure.
What is disclosed is a system and method for forecasting and imputing an unknown vital measurement of a patient. Temporally successive patient vital measurements are received which comprise irregularly sampled observations {y1, . . . , yN}, where yj denotes the jth observation at time tj, and N is the number of samples. The vital measurements are then provided to a model trained using historical data of patient vital measurements. The model generates a parameter set θ=(A,B,C), where A is a state transition matrix, B is a control matrix, and C is a matrix which maps state-space variables to observation variables. The parameters are used to obtain state-space variable zt which, in turn, is used to forecast an unknown observation yN+1 or to impute an unknown observation yt, where 1&lt;t&lt;N. The historical data is then updated with the forecasted observation yN+1 or the imputed unknown observation yt.
Influenza vaccines include hemagglutinin from at least one influenza A virus strain and at least one influenza B virus strain. They also include an oil-in-water emulsion adjuvant with submicron oil droplets, comprising squalene. In some embodiments the hemagglutinin concentration is &gt;12[mu]g/ml per strain. In some embodiments the squalene concentration is &lt;19mg/ml. In some embodiments the vaccine is mercury-free. In some embodiments the vaccine has a unit dose volume between 0.2-0.3mL. In some embodiments the squalene concentration is 9.75mg/mL or 4.88mg/mL. In some embodiments the vaccine includes antigens from two influenza A virus strains and two influenza B virus strains.
The present invention relates to compositions and methods comprising resveratrol and uses thereof in the treatment of Alzheimer&#39;s disease, traumatic brain injury, and the brain associated pathologies associated therewith. The methods provide for the use of transmucosal delivery formulations that provide enhanced bioavailability of resveratrol in phamacologically active levels to a subject. The formulations are employed in treatment methods that include a regimen of one to several daily dosages of the formulation. The formulation includes resveratrol and a solubilizer in a defined weight ratio. Particular embodiments include transmucosal delivery of resveratrol from the composition. Methods for treating/inhibiting the symptoms associated with Alzheimer&#39;s disease and traumatic brain injury, employing the pharmaceutical compositions, in a subject, such as a human, are described.
PURPOSE:To provide a polymerizable composition which can be stored at room temperature for a long period of time by using a specified aromatic sulfinate as a polymerization initiator in the production of a polymerizable composition. CONSTITUTION:A polymerizable composition is produced by mixing a polymerization initiator (A) comprising a sulfinate of formula I (wherein R&lt;1&gt; and R&lt;5&gt; are each a 2-6C substituent; R&lt;2&gt;, R&lt;3&gt; and R&lt;4&gt; are each an atom or a substituent inert to component B; M&lt;n+&gt; is an n-valent cation; and n is 1-4), e.g. formula II or III, with a polymerizable monomer (B) (e.g. methyl methacrylate or ethylene glycol diacrylate). In this way, the reaction of component A with component B at room temperature can be prevented, and the storage stability of the polymerizable composition can be improved. This composition can be polymerized rapidly by adding an oxidizing agent thereto just before use, and therefore it can be desirably used as a dental adhesive or the like.
PURPOSE: To obtain the subject new compound capable of suppressing the production of tumor necrosis factor by antagonistically acting on a lipopolysaccharide, thus useful for preventing or treating septicemic shock. CONSTITUTION: This new compound is expressed by formula I (R is an amino acid or ester thereof, R-CO represents that an amide bond has been formed; (n) and (m) are each 6-16; X is O or S; where, excepting ornithine-contg. lipid II as a natural-type optically active form and serine-contg. lipid), e.g. [3- hydroxy-2(S)-[15-methyl-3(R)-(13methyltetradecanoyloxy) hexadecanoyl]amino]propionic acid. This compound of formula I is obtained by condensation reaction between a compound of formula II (R&lt;1&gt; is a carboxyl- protecting group; Y is OH or SH) and a compound of formula III in the presence or absence of a condensation agent followed by, if desired, removing the carboxyl-protecting group in the resultant condensate.
The invention is a skin whitening supplement containing Probiotic culture. Probiotics are beneficial for human health for it facilitate proper absorption of vitamins, minerals, nutrients and other ingredients in the formulation. Probiotics also aid in improving the skin&#39;s condition. The formula is a combination of a Probiotic culture and five potent active ingredients in beauty and whitening. The four potent antioxidants for whitening are: Glutathione-reduced, N-Acteyl Cysteine, Alpha Lipoic Acid and Sodium Ascorbate. Collagen, a major structural protein of the skin, was added to keep the skin healthy. The Probiotic culture in the formulation is the patented strain of Lactobacillus casei KE-99, validated and proven to be effective probiotic compared to other strains. The six active ingredients are combined in one as a whitening supplement for an easy consumption in a vegetable source hydroxylpropyl methylcellulose capsule, or as tablets and even in a powder form.
The invention provides a traditional Chinese medicine composition used for treating Alzheimer&#39;s dementia. The composition comprises traditional Chinese medicine raw materials used as active components, and pharmaceutic adjuvants. The traditional Chinese medicine raw materials used to prepare the active components comprise 6-12 weight parts of polygala root, 10-20 weight parts of radix codonopsis and 5-15 weight parts of liquorice. According to the invention, effects on quasi-AD rats diseases of which are caused by injection of A[beta]1-40 to bilateral hippocampus, effects on memory acquisition disorder type AD model mice diseases of which are caused by scopolamine, and the like are tested. Test results show that the composition can improve learning and memory abilities of the AD model rats, and can increase intracephalic energy metabolism, thereby improving brain functions, etc.. Therefore, the traditional Chinese medicine composition can be applied for preparing medicines used for treating the Alzheimer&#39;s dementia. The composition is in forms of tablets, capsules and granules, thus improving medicine taking compliance for patients. The preparations are stable and easily prepared, and suitable for industrial production. New medicines used for treating the Alzheimer&#39;s dementia are provided for clinic. The composition has great application value and social benefit.
PROBLEM TO BE SOLVED: To obtain a cosmetic giving excellent feeling such as dampishness and moistness, high humectant effect and softening effect to the skin by including a fruit water separated in the process for the concentration of fruit juice. SOLUTION: A cosmetic such as beauty wash, milky lotion, various creams, foundation, face lotion, rouge, beauty liquid and pack is compounded with a fruit water separated in a fruit juice concentrating process. The content of glucose and/or fructose in the fruit water is preferably &lt;=0.5 wt.% and the compounding amount of the fruit water is preferably &gt;=1 wt.% based on the produced cosmetic. Any fruit usable as a raw material for concentrated fruit juice can be used as the fruit and the examples of the fruit are apple, tangerine, orange and peach. The fruit water is e.g. water separated in a reverse osmosis membrane treatment of fruit juice comprising the passing of fruit juice through a tubular semipermeable membrane and the application of pressure to exclude water through the wall of the tubular membrane.